CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

INTRODUCTION: CD40 ligand (CD40L) blockade has demonstrated efficacy in experimental autoimmune models. However, clinical trials of hu5c8, an anti-human CD40L IgG(1) antibody, in systemic lupus erythematosus (SLE) were halted due to an increased incidence of thrombotic events. This study evaluated C...

Descripción completa

Detalles Bibliográficos
Autores principales: Shock, Anthony, Burkly, Linda, Wakefield, Ian, Peters, Christopher, Garber, Ellen, Ferrant, Janine, Taylor, Frederick R., Su, Lihe, Hsu, Yen-Ming, Hutto, David, Amirkhosravi, Ali, Meyer, Todd, Francis, John, Malcolm, Sarah, Robinson, Martyn, Brown, Derek, Shaw, Stevan, Foulkes, Roland, Lawson, Alastair, Harari, Olivier, Bourne, Timothy, Maloney, Alison, Weir, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558773/
https://www.ncbi.nlm.nih.gov/pubmed/26335795
http://dx.doi.org/10.1186/s13075-015-0757-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558773/
https://www.ncbi.nlm.nih.gov/pubmed/26335795
http://dx.doi.org/10.1186/s13075-015-0757-4

Ejemplares similares